Morepen Laboratories Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Morepen Laboratories Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash paid for 30% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares. Lower than 86% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹45Over the last 3 years, every ₹100 of reported profit came with ₹45 of operating cash.
Lower than 82% of Healthcare companies in India.
Self-Funding Ratio
0.3×Over the last 3 years its own operating cash paid for 30% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 86% of Healthcare companies in India.
Cash Locked Ratio
₹16For every ₹100 of sales, ₹16 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹17 tied up three years earlier.
Less money tied up than 67% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
₹15Sales grew 27% in 3 years; of every extra ₹100 of sales, ₹15 became extra profit.
Lower than 56% of Healthcare companies in India.
Asset Productivity Ratio
+27% / +74%In 3 years sales changed by +27% while total assets changed by +74%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.5×Debt due within a year is covered 0.5 times by its yearly operating cash.
Lower than 69% of Healthcare companies in India.
Cash Cushion Ratio
−2%Debt, after subtracting cash, equals 2% of its market value (net debt).
Lower than 54% of Healthcare companies in India.
Tangible Assets Ratio
94%Of every ₹100 the company owns, ₹94 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 62% of Healthcare companies in India.
Tangible Net Worth Ratio
90%Of every ₹100 of net worth, ₹90 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 61% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Morepen Laboratories Limited owes ₹0.36 for every ₹1 it owns. Net profit fell 20% in the year to Mar 2026, and grew 35% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
46.0Investors pay ₹46.0 for every ₹1 of Morepen Laboratories Limited's yearly profit, higher than 63% of Healthcare companies in India.
P/B ratio
5.17The share price is 5.17 times Morepen Laboratories Limited's book value per share, higher than 58% of Healthcare companies in India.
Market cap
₹6,448 CrThe total market value of all of Morepen Laboratories Limited's shares at today's price (share price × number of shares), larger than 54% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹1,246 CrWhat Morepen Laboratories Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹22.75Net worth divided by the number of shares. The share price of ₹117.67 is 5.2 times this, which is the P/B above.
Return on equity (ROE)
11.6%Morepen Laboratories Limited earned 11.6% on its shareholders' money over the last year, lower than 58% of Healthcare companies in India.
Owes vs Owns
0.36×Morepen Laboratories Limited owes ₹0.36 for every ₹1 it owns (low), lower than 55% of Healthcare companies in India.
Dividend yield
0.15%Morepen Laboratories Limited pays 0.15% of its share price as dividends a year, lower than 77% of dividend-paying Healthcare companies in India.
Revenue growth
-0%Revenue fell 0% in the year to Mar 2026, and grew 8% a year on average over 3 years.
Profit growth
-20%Net profit fell 20% in the year to Mar 2026, and grew 35% a year on average over 3 years.
Profit margin
5.3%Morepen Laboratories Limited keeps ₹5 of every ₹100 of revenue as net profit.
Cash quality
0.3×Cash from Morepen Laboratories Limited's business was 0.3× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
5.5×Morepen Laboratories Limited's operating profit covered its interest costs 5.5 times in the year to Mar 2026.
Cash vs debt
Net debtMorepen Laboratories Limited had ₹154 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Morepen Laboratories Limited's P/E ratio?
Investors pay ₹46.0 for every ₹1 of Morepen Laboratories Limited's yearly profit, higher than 63% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Morepen Laboratories Limited: ₹6,448 Cr ÷ ₹1,246 Cr (31 Mar 2026) = 5.2.
What is Morepen Laboratories Limited's return on equity?
Morepen Laboratories Limited earned 11.6% on its shareholders' money over the last year, lower than 58% of Healthcare companies in India.
How much does Morepen Laboratories Limited owe compared with what it owns?
Morepen Laboratories Limited owes ₹0.36 for every ₹1 it owns (low), lower than 55% of Healthcare companies in India.
Does Morepen Laboratories Limited pay a dividend?
Yes. Morepen Laboratories Limited pays 0.15% of its share price as dividends a year, lower than 77% of dividend-paying Healthcare companies in India.
Is Morepen Laboratories Limited's revenue growing?
Revenue fell 0% in the year to Mar 2026, and grew 8% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.